TABLE 4.
Candidate dengue vaccines in preclinical developmenta
| Vaccine type | No. of candidates | Developer(s) |
|---|---|---|
| Live attenuated | 3 | Chiang Mai University, Arbovax, Beijing Institute of Microbiology and Epidemiology |
| Inactivated | 1 | NMRC |
| Recombinant subunit | 4 | ICGEB-India, National Health Research Institutes (Taiwan) |
| DNA | 4 | Inovio, Kobe University, CDC, NMRC, Fiocruz |
| Virus-like particles | 4 | Cytos, ICGEB-India, Kobe University, NCGEB-Thailand |
| Virus-vectored | 5 | ICGEB-India, GenPhar/NMRC, University of North Carolina, University of Texas, Themis Bioscience/Institut Pasteur |
a
CDC, U.S. Centers for Disease Control and Prevention; Fiocruz, Fundação Oswaldo Cruz; ICGEB-India, International Center for Genetic Engineering and Biotechnology; NCGEB-Thailand, National Center for Genetic Engineering and Biotechnology; NMRC, U.S. Naval Medical Research Center.